Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats

Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.
Neuropharmacology (Impact Factor: 5.11). 08/2011; 62(1):373-84. DOI: 10.1016/j.neuropharm.2011.08.013
Source: PubMed


Patients with post-traumatic stress disorder (PTSD) frequently complain of having sleep disturbances, such as insomnia and rapid eye movement (REM) sleep abnormality. Cannabidiol (CBD), a psycho-inactive constituent of marijuana, reduces physiological non-REM (NREM) sleep and REM sleep in normal rats, in addition to generating its anxiolytic effect. However, the effects of CBD on anxiety-induced sleep disturbances remain unclear. Because anxiety progression is caused by persistent stress for a period of time, we employed the repeated combination tests (RCT) consisting of a 50-min open field (OF) and a subsequent 10-min elevated plus-maze (EPM) for four consecutive days to simulate the development of anxiety. Time spent in the centre arena of OF and during open arms of the EPM was substantially decreased in latter days of RCT, suggesting the habituation, which potentially lessens anxiety-mediated behavioural responses, was not observed in current tests. CBD microinjected into the central nucleus of amygdala (CeA) significantly enhanced time spent in centre arena of OF, increased time during the open arms and decreased frequency of entry to the enclosed arms of EPM, further confirming its anxiolytic effect. The decrease of NREM sleep during the first hour and the suppression of REM sleep during hours 4-10 after the RCT represent the similar clinical observations (e.g. insomnia and REM sleep interruption) in PTSD patients. CBD efficiently blocked anxiety-induced REM sleep suppression, but had little effect on the alteration of NREM sleep. Conclusively, CBD may block anxiety-induced REM sleep alteration via its anxiolytic effect, rather than via sleep regulation per se. This article is part of a Special Issue entitled 'Anxiety and Depression'.

Download full-text


Available from: Fang-Chia Chang, Mar 06, 2014
  • Source
    • "Similar results were obtained by injecting CBD into the lateral hypothalamus during the lights-on period at doses of 10 or 20 micrograms/1 microliter (Murillo-Rodríguez et al. 2008, 2011). Recently, Hsiao et al. (2012) showed that CBD efficiently blocked anxiety-induced REM sleep suppression. Taken together, these data suggest that CBD promotes alertness; however the mechanisms of action of this cannabinoid for its effect on sleep remain unclear. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sleep is a universal phenomenon that occurs in every species studied so far. A normal sleep period fluctuates in a regular cycle of two basic forms: slow wave sleep (SWS) and rapid eye movement (REM) sleep. The sleep–wake cycle is modulated by diverse brain circuits and neuromodulators as well as by several endogenous and exogenous molecules, including cannabinoids. Here, we describe the effects of certain cannabis-derived and synthetic cannabinoids on sleep. Additionally, we provide an overview of current knowledge about potential uses of natural or synthetic cannabinoids for the treatment of sleep disorders.
    Handbook of Cannabis, Edited by Roger Pertwee, 12/2014: chapter 29: pages 538-46; Oxford University Press., ISBN: 9780199662685
  • Source
    • "Several parameters, such as defecation and time in a center within the first 5 min, likely gauge some aspects of emotionality including anxiety (Hsiao et al., 2012). Animals were treated in an open field apparatus in a room. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abnormal adaptation of the stress-response system following traumatic stress can lead to alterations in the hypothalamic-pituitary-adrenal (HPA) axis that may contribute to the development of post-traumatic stress disorder (PTSD). The present study used several behavioral tests to investigate the anxiolytic-like and antidepressant activity of L-tetrahydropalmatine (L-THP) in an experimental rat model of anxiety and depression induced by single prolonged stress (SPS), an animal model of PTSD. Male rats were treated intraperitoneally (i.p.) with vehicle or varied doses of THP 30 min prior to SPS for 8 consecutive days. Daily THP (50 mg/kg) administration significantly increased the number and duration of open arm visits in the elevated plus maze (EPM) test, reduced the anxiety index, increased the risk assessment, and increased the number of head dips over the borders of the open arms after SPS. THP was also associated with increased time spent at the center of the open field, reduced grooming behaviors in the EPM test, and reduced time spent immobile in the forced swimming test (FST). It also blocked the decrease in neuropeptide Y (NPY) and the increase in corticotrophin-releasing factor (CRF) expression in the hypothalamus. This is the first study to determine that THP exerts pronounced anxiolytic-like and antidepressant effects on the development of the behavioral and biochemical symptoms associated with PTSD, indicating its prophylactic potential. Thus, THP reversed several behavioral impairments triggered by the traumatic stress of SPS and is a potential non-invasive therapeutic intervention for PTSD.
    Biomolecules and Therapeutics 05/2014; 22(3):213-22. DOI:10.4062/biomolther.2014.032 · 1.73 Impact Factor
  • Source
    • "This effect was further confirmed by several subsequent studies in which the systemic (Moreira et al., 2006; Resstel et al., 2006; Malone et al., 2009; Casarotto et al., 2010; Long et al., 2010; Deiana et al., 2012; Stern et al., 2012) or local (i.c.v. or cisterna magna) (Bitencourt et al., 2008; Granjeiro et al., 2011) administration of CBD decreased anxiety-like behavior in rodents. Interestingly, this effect seems to target a specific brain region: injection of CBD into the dlPAG, the bed nucleus of the stria terminalis (BNST), the prelimbic PFC (plPFC) or the central nucleus of the amygdala (CeA) exerted anxiolytic effects (Campos & Guimarães, 2008; Lemos et al., 2010; Soares et al., 2010; Gomes et al., 2011b, 2012; Hsiao et al., 2012 "
    [Show abstract] [Hide abstract]
    ABSTRACT: The endocannabinoid system (ECS), comprising two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle Δ(9)-tetrahydrocannabinol [Δ(9)-THC]), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and the proteins for endocannabinoid biosynthesis and degradation, has been suggested as a pro-homeostatic and pleiotropic signaling system activated in a time- and tissue-specific way during physiopathological conditions. In the brain activation of this system modulates the release of excitatory and inhibitory neurotransmitters and of cytokines from glial cells. As such, the ECS is strongly involved in neuropsychiatric disorders, particularly in affective disturbances such as anxiety and depression. It has been proposed that synthetic molecules that inhibit endocannabinoid degradation can exploit the selectivity of endocannabinoid action, thus activating cannabinoid receptors only in those tissues where there is perturbed endocannabinoid turnover due to the disorder, and avoiding the potential side effects of direct CB1 and CB2 activation. However, the realization that endocannabinoids, and AEA in particular, also act at other molecular targets, and that these mediators can be deactivated by redundant pathways, has recently led to question the efficacy of such approach, thus opening the way to new multi-target therapeutic strategies, and to the use of non-psychotropic cannabinoids, such as cannabidiol (CBD), which act via several parallel mechanisms, including indirect interactions with the ECS. The state of the art of the possible therapeutic use of endocannabinoid deactivation inhibitors and phytocannabinoids in mood disorders is discussed in this review article.
    Pharmacology [?] Therapeutics 12/2012; 138(1). DOI:10.1016/j.pharmthera.2012.12.002 · 9.72 Impact Factor
Show more